OSR Health, Inc.

OSR Holdings, Inc. is a global healthcare holding company that acquires, builds, and operates healthcare-related businesses. Operating through three wholly owned subsidiaries under a hub-and-spoke model, the company focuses on developing oral T-cell immunotherapies for cancer treatment, creating design-augmented biologics for bone and cartilage regeneration as well as age-related degenerative diseases, and distributing neurovascular surgical devices and intervention systems in Korea. Its customers and end users include patients and healthcare providers requiring targeted interventions for oncology, degenerative disorders, and neurovascular procedures.

The company operates internationally with facilities and operations in South Korea and Switzerland, alongside an office in the United States. Its subsidiary portfolio encompasses three operating businesses, including Vaximm and Darnatein, maintaining an intellectual property portfolio spanning ten patent families across multiple regions, such as the United States, Europe, Japan, China, India, Australia, Canada, and South Korea. OSR Holdings maintains its principal executive offices in Bellevue, Washington.

Summary of the business section of OSR Health's latest annual report, written by StockData.

“As of December 31, 2025, we had 22 full-time employees whom”